ArticleBiotechnology journal2025
Rapid At-Line AAVX Affinity HPLC: Enabling Process Analytical Technology for Bioprocess Development of Adeno-Associated Virus Vectors.
Article in Biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Continuous Biomanufacturing of Recombinant Adeno-Associated Virus.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant adeno-associated virus (rAAV) vectors have emerged as a new class of therapeutic modal with the promise to treat or even cure hereditary and acquired diseases, but their consistent and efficient production remains challenging. To address these inadequacies, the implementation of process analytical technology (PAT) principles for the development of rAAV-based gene therapies holds the prospect of promoting greater product and process understanding. However, a substantial lack of suitable analytical tools during both upstream and downstream processing (DSP) hinders the ability to fully realize the potential of PAT for rAAVs. To fill this gap, our recently described AAVX affinity-based high-performance liquid chromatography (HPLC) method was assessed as an at-line PAT tool to determine the capsid titer and the percentage of filled capsids at various stages of the production process. Leveraging the fast and robust provision of these parameters, even for challenging samples, the benefits of this approach for improved process monitoring and control were demonstrated for samples generated both during fermentation and DSP. Given the versatility of our developed analytical method for different rAAV serotype and payload combinations, we eventually highlight its expansive opportunities to streamline process development and therefore contributing to high-quality and cost-efficient production of rAAV-based gene therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.